Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01563341 · ClinicalTrials.gov registry record · NA
Tandem DBS for Parkinson's Disease: A Pilot Study Utilizing STN/GPi + Hypothalamic Stimulation
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT01563341: Completed NA study, sponsored by Mayo Clinic.
NCT01563341 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01563341, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
Does dual hemispheric stimulation of the subthalamic nucleus (STN) and fornix/hypothalamus potentially improve cognitive function in patients with Parkinsons disease.
Interventions
- DEVICE Deep brain stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-04 |
| Est. Completion | 2023-10-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01563341
The ClinicalTrials.gov registry entry for NCT01563341 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Deep brain stimulation is the first listed.
NCT01563341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01563341 about?
NCT01563341 is a clinical study titled "Tandem DBS for Parkinson's Disease: A Pilot Study Utilizing STN/GPi + Hypothalamic Stimulation". Does dual hemispheric stimulation of the subthalamic nucleus (STN) and fornix/hypothalamus potentially improve cognitive function in patients with Parkinsons disease.
What is the current status of trial NCT01563341?
This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2012-04. Estimated completion is 2023-10-18.
What interventions are being tested in trial NCT01563341?
The interventions under investigation include: Deep brain stimulation (DEVICE).
Who is sponsoring clinical trial NCT01563341?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.